SEC Filings

8-K
AVEXIS, INC. filed this Form 8-K on 06/07/2017
Entire Document
 

 

EXHIBIT INDEX

 

Exhibit

 

 

Number

 

Exhibit Description

99.1

 

Press Release, dated June 7, 2017, titled “AveXis and REGENXBIO Announce New Exclusive Worldwide Licenses for the Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector.”

 

5



© AveXis, Inc. All Rights Reserved.